id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-P-5787-0231,FDA,FDA-2017-P-5787,Melcangi_Methylation of SRD5A2 in CSF of PFS Pts (Endocr Connect 2019),Supporting & Related Material,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T16:07:15Z,,0,0,0900006484984797
FDA-2017-P-5787-0222,FDA,FDA-2017-P-5787,CMDh Recommendation re Anxiety in Propecia SPC_EMA (Apr 2018),Supporting & Related Material,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T15:27:24Z,,0,0,0900006484984768
FDA-2017-P-5787-0223,FDA,FDA-2017-P-5787,"Diviccaro_Finasteride, Hippocampal Neurogenesis and Neuroinflammation in Rats (Psychneuroendocrin 2019)",Supporting & Related Material,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T15:28:17Z,,0,0,0900006484984769
FDA-2017-P-5787-0230,FDA,FDA-2017-P-5787,Levine_Court let Merck hide secrets (Reuters 9-11-19),Supporting & Related Material,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T16:06:26Z,,0,0,0900006484984796
FDA-2017-P-5787-0232,FDA,FDA-2017-P-5787,Nguyen and Trinh_Suicidality and Psychological AEs w Finasteride (JAMA Derm 2020),Supporting & Related Material,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T16:09:31Z,,0,0,0900006484984798
FDA-2017-P-5787-0241,FDA,FDA-2017-P-5787,Summary of Product Characteristics_ANSM_English (Dec 2019),Supporting & Related Material,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T16:34:25Z,,0,0,090000648498449a
FDA-2017-P-5787-0224,FDA,FDA-2017-P-5787,Gulbinovic_Final Assessment Report of PSUR (Sweden MPA 2007),Supporting & Related Material,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T15:29:58Z,,0,0,0900006484984791
FDA-2017-P-5787-0235,FDA,FDA-2017-P-5787,Petition Supplement 2 Post-Finasteride Syndrome Foundation,Notice,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T17:17:17Z,,0,0,0900006484984494
FDA-2017-P-5787-0226,FDA,FDA-2017-P-5787,Kaufman_Finasteride Rx for AGA (J Am Acad Dermatol 1998),Supporting & Related Material,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T15:31:57Z,,0,0,0900006484984793
FDA-2017-P-5787-0228,FDA,FDA-2017-P-5787,Khera and Mirabel_Penile Vascular Abnormalities in PFS (Translat Androl Urol 2020),Supporting & Related Material,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T15:46:53Z,,0,0,0900006484984794
FDA-2017-P-5787-0236,FDA,FDA-2017-P-5787,Propecia Proposed Prescribing Info_Revision Marks (2002),Supporting & Related Material,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T16:27:53Z,,0,0,0900006484984495
FDA-2017-P-5787-0238,FDA,FDA-2017-P-5787,Propecia Summary of Product Characteristics_MHRA UK (Jun 2018),Supporting & Related Material,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T16:29:49Z,,0,0,0900006484984497
FDA-2017-P-5787-0240,FDA,FDA-2017-P-5787,Reminder of Risk of Psychiatric and Sexual Disorders_ANSM webpage (Feb 2019),Supporting & Related Material,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T16:33:26Z,,0,0,0900006484984499
FDA-2017-P-5787-0237,FDA,FDA-2017-P-5787,Propecia Summary of Product Characteristics_ANSM France (Dec 2019),Supporting & Related Material,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T16:28:52Z,,0,0,0900006484984496
FDA-2017-P-5787-0225,FDA,FDA-2017-P-5787,Irwig_Finasteride and Suicide Case Series (Dermatol 2020),Supporting & Related Material,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T15:30:45Z,,0,0,0900006484984792
FDA-2017-P-5787-0229,FDA,FDA-2017-P-5787,Letter to Health Professionals_Reminder of Risk of Psychiatric and Sexual Disorders_ANSM France (Feb 2019),Supporting & Related Material,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T15:52:35Z,,0,0,0900006484984795
FDA-2017-P-5787-0227,FDA,FDA-2017-P-5787,Godar and Bortolato_Finasteride Reduces Response to Stressful and Rewarding Stimuli (Biomolec 2019),Supporting & Related Material,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T15:41:44Z,,0,0,0900006484984790
FDA-2017-P-5787-0233,FDA,FDA-2017-P-5787,Periodic Safety Update Report _19_Merck (Nov 2006),Supporting & Related Material,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T16:24:23Z,,0,0,0900006484984799
FDA-2017-P-5787-0234,FDA,FDA-2017-P-5787,Petition Supplement 1 Post-Finasteride Syndrome Foundation,Notice,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T17:16:41Z,,0,0,0900006484984493
FDA-2017-P-5787-0239,FDA,FDA-2017-P-5787,Red Hand Letter re Finasteride_BfArM Germany (Jul 2018),Supporting & Related Material,Background Material,2020-12-03T05:00:00Z,2020,12,,,2020-12-03T16:30:50Z,,0,0,0900006484984498